Gene set enrichment analysis (GSEA) revealed upregulation of several oncogenic pathways upon SETD2 loss, including the KRAS transcriptional signature, the PTEN-loss transcriptional signature, and PRC2-repressed targets identified in liver cancer (20), and malignant peripheral nerve sheath tumors (MPNST) (21) (Figure 2A and Supplemental Table 1). This evidence concerns the gene SETD2 and malignant peripheral nerve sheath tumor.